GLP-1 and GIP Receptor Agonists: Expanding Role in Cardiovascular-Kidney-Metabolic Health
Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across cardiovascular, kidney, and metabolic conditions with emerging evidence for dual agonism.
Quick Facts
What This Study Found
Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across cardiovascular, kidney, and metabolic conditions with emerging evidence for dual agonism.
Key Numbers
Review covers large clinical outcome trials establishing GLP-1 RAs as guideline-directed therapies for multiple CKM conditions.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The Bigger Picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
What This Study Doesn't Tell Us
Study limitations in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to other evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across
- Evidence Grade:
- Evidence level based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.
- Published In:
- Cardiology clinics, 43(3), 415-432 (2025)
- Authors:
- Alicic, Radica Z(2), Neumiller, Joshua J(7)
- Database ID:
- RPEP-09867
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean for patients?
Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across cardiovascular, kidney, and metabolic conditions with emerging evidence for dual agonism.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09867APA
Alicic, Radica Z; Neumiller, Joshua J. (2025). Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.. Cardiology clinics, 43(3), 415-432. https://doi.org/10.1016/j.ccl.2024.12.003
MLA
Alicic, Radica Z, et al. "Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.." Cardiology clinics, 2025. https://doi.org/10.1016/j.ccl.2024.12.003
RethinkPeptides
RethinkPeptides Research Database. "Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insuli..." RPEP-09867. Retrieved from https://rethinkpeptides.com/research/alicic-2025-role-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.